Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 10:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Suvorexant Placebo Clear all
Completed Phase 4 Interventional Results available

Suvorexant and Trauma Related Insomnia

NCT02704754
View directory record Official record
Conditions
Insomnia, Posttraumatic Stress Disorder
Interventions
suvorexant, placebo
Drug · Other
Lead sponsor
Howard University
Other
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 30, 2026, 10:49 AM EDT
Completed Phase 4 Interventional Results available

The Role of Orexin in Human Panic Disorder

NCT02593682
View directory record Official record
Conditions
Panic Disorder
Interventions
suvorexant, placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Sep 30, 2026, 10:49 AM EDT
Not yet recruiting Phase 4 Interventional

Suvorexant 3 - PE-PC

NCT07686731
View directory record Official record
Conditions
PTSD - Post Traumatic Stress Disorder, Insomnia, TBI (Traumatic Brain Injury)
Interventions
Suvorexant, Placebo, Prolonged Exposure Therapy for Primary Care (PE-PC)
Drug · Behavioral
Lead sponsor
Northern California Institute of Research and Education
Other
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 30, 2026, 10:49 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms

NCT06484075
View directory record Official record
Conditions
Healthy Volunteers, Alcohol Use Disorder (AUD)
Interventions
Placebo, Suvorexant
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Sep 30, 2026, 10:49 AM EDT
Completed Phase 2 Interventional Results available

Medical Management of Sleep Disturbance During Opioid Tapering

NCT03789214
View directory record Official record
Conditions
Opioid Dependence, Opioid Withdrawal, Sleep Disturbance
Interventions
Placebo oral capsule, Low Dose Suvorexant, High Dose Suvorexant
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 30, 2026, 10:49 AM EDT
Completed Phase 2 Interventional Results available

Suvorexant for Opioid/Stimulant Co-use

NCT05546515
View directory record Official record
Conditions
Opioid Use Disorder, Stimulant Use Disorder
Interventions
Suvorexant (dual orexin receptor antagonist), Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 30, 2026, 10:49 AM EDT
Recruiting Phase 2 Interventional

Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking

NCT07214207
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Suvorexant 10 mg, Placebo
Drug · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 30, 2026, 10:49 AM EDT
Completed Phase 2 Interventional Results available

Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use

NCT02785406
View directory record Official record
Conditions
Cocaine Use Disorder, Anxiety
Interventions
suvorexant, Placebo (for suvorexant)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
19 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 30, 2026, 10:49 AM EDT
Completed Phase 4 Interventional Results available

Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs

NCT03312517
View directory record Official record
Conditions
Insomnia
Interventions
Suvorexant 10 mg, Suvorexant 20 mg, Placebo oral capsule
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Novi, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Sep 30, 2026, 10:49 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Trial of Suvorexant for Sleep in Children With Autism

NCT05546554
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
13 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Sep 30, 2026, 10:49 AM EDT
Not yet recruiting Phase 4 Interventional

The Effects of Orexin Antagonism on Fear Extinction in PTSD

NCT06788522
View directory record Official record
Conditions
Insomnia, PTSD
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
40,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
San Francisco, California • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 30, 2026, 10:49 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study

NCT04273776
View directory record Official record
Conditions
Performance Enhancing Product Use
Interventions
Suvorexant 10 mg, Zolpidem, Placebos
Drug
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 39 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 30, 2026, 10:49 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia

NCT04706091
View directory record Official record
Conditions
Restless Legs Syndrome, Insomnia, Sleep Disorder
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 85 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Sep 30, 2026, 10:49 AM EDT
Completed Phase 4 Interventional Results available

Suvorexant and Sleep/Delirium in ICU Patients

NCT04092894
View directory record Official record
Conditions
Insomnia, Sleep Fragmentation, Sleep Initiation and Maintenance Disorders, Postoperative Delirium
Interventions
Suvorexant 20 mg, Placebo oral tablet
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 30, 2026, 10:49 AM EDT
Completed Phase 2 Interventional Results available

Suvorexant to Reduce Symptoms of Nicotine Use

NCT04234997
View directory record Official record
Conditions
Smoking Cessation
Interventions
Suvorexant 20 mg, Suvorexant 0mg
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 30, 2026, 10:49 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Measuring Acute Drug Demand in Humans

NCT05829655
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Dependence
Interventions
Drug A (Blinded Drug), Drug B (Blinded Drug), Drug C (Blinded Drug), Drug D (Blinded Drug), Suvorexant (20mg/day), Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 30, 2026, 10:49 AM EDT
Not listed Phase 4 Interventional

Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic Insomnia

NCT03768713
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Montana State University
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Sep 30, 2026, 10:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder

NCT02849548
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
suvorexant, placebo
Drug · Other
Lead sponsor
Howard University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Sep 30, 2026, 10:49 AM EDT
Completed Phase 4 Interventional Results available

Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes

NCT03818581
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Insomnia, Sleep Disorder, Inflammation
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 30, 2026, 10:49 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Orexin s Role in the Neurobiology of Substance Use Disorder

NCT05630781
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Belsomra, Placebo, Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Sep 30, 2026, 10:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers

NCT02491788
View directory record Official record
Conditions
Sleep Disorder, Shift-Work
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
VA Palo Alto Health Care System
Federal
Eligibility
20 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Sep 30, 2026, 10:49 AM EDT
Terminated Phase 2 Interventional Results available

The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder

NCT05711862
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
suvorexant (SUVO), Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 30, 2026, 10:49 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Suvorexant on Post-operative Sleep Disturbance

NCT05823844
View directory record Official record
Conditions
Postoperative Insomnia, Postoperative Delirium
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
50 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 30, 2026, 10:49 AM EDT
Terminated Phase 2 Interventional

Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder

NCT04262193
View directory record Official record
Conditions
Opioid-use Disorder, Sleep
Interventions
Suvorexant, Suvorexant Placebo
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Sep 30, 2026, 10:49 AM EDT